ACUTE LYMPHOBLASTIC LEUKEMIA

This study tests a new treatment for children and young adults (ages 3-39) with B-cell cancers like leukemia or lymphoma that have come back after standard therapy. The treatment uses a patient's own immune cells, which are modified in a lab to target two cancer proteins (CD19 an…

This study tests whether removing a specific type of immune cell (naive T cells) from donated stem cells can prevent chronic graft-versus-host disease (GVHD) in children and young adults with blood cancers. GVHD occurs when donor cells attack the patient's body, causing long-term…

This early-phase study tests whether adding the drug calaspargase pegol to standard chemotherapy (Hyper-CVAD) is safe and tolerable for young adults newly diagnosed with acute lymphoblastic leukemia (ALL). About 7 participants will receive the combination after their first round …

This study tests a combination of two targeted drugs (dasatinib and venetoclax) plus chemotherapy in children and young adults up to age 21 whose leukemia or lymphoma has returned or not responded to standard treatment. The goal is to find the best dose and see if the combo can s…

This study tests whether adding newer immunotherapy drugs to standard treatment can improve survival and reduce the need for stem cell transplants in adults with acute lymphoblastic leukemia (ALL). About 1,200 participants aged 18-65 with newly diagnosed ALL will be assigned to o…

This study tests whether a targeted drug called inotuzumab ozogamicin works better than standard chemotherapy (ALLR3) for children aged 1 to 17 with high-risk or very high-risk B-cell acute lymphoblastic leukemia that has come back for the first time. About 100 participants will …

This study tests whether a new chemotherapy combination (TmBU) works better than the standard one (mBUCY) before a stem cell transplant in people with high-risk or hard-to-treat leukemia. About 48 adults aged 65 or younger will be randomly assigned to one of the two regimens. The…

This study is for people with blood cancers like leukemia or lymphoma who need a stem cell transplant from an unrelated donor. It compares two ways to prevent graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body. One method uses a d…

This study tests a CAR T-cell therapy called KTE-X19 in adults with B-cell acute lymphoblastic leukemia who are in remission but still have tiny amounts of cancer cells (minimal residual disease). The goal is to see if the treatment can clear these leftover cells and keep patient…

This study tests a new drug, bleximenib, for people with acute leukemia that has come back or not responded to other treatments. The drug targets specific genetic changes in leukemia cells. The study has two phases: first to find the best dose and check safety, then to see how we…

This study compares two strategies to lower the risk of graft-versus-host disease (GVHD) in people with acute leukemia or myelodysplastic syndrome (MDS) who are getting a donor stem cell transplant. Participants will receive either a treatment that removes certain immune cells fr…

This early-phase study is testing a new way to prepare donor stem cells, called Orca-Q, for people with certain blood cancers (like leukemia) who need a stem cell transplant. The goal is to see if this engineered graft is safe and helps the body accept the new cells without sever…

This study tests a new drug, MK-1045, for people with a type of blood cancer (B-cell acute lymphoblastic leukemia) that has come back or stopped responding to treatment. The trial has two parts: first, finding a safe and tolerable dose, then checking how well it works. About 203 …

This study tests a combination of two drugs, blinatumomab and ponatinib, in adults with a specific type of acute lymphoblastic leukemia (ALL) that has the Philadelphia chromosome. The goal is to see if this combo can better control the disease, especially in patients whose cancer…

This study tests a new way to prepare donor stem cells for transplant in people with blood cancers like leukemia. By removing certain immune cells from the donated cells, researchers hope to lower the risk of graft-versus-host disease, a serious side effect. The study involves 70…

This study tests whether a cord blood transplant (using stem cells from donated umbilical cord blood) can help children and young adults up to age 26 with blood cancers like leukemia or lymphoma. Participants receive the transplant as their first or second treatment. The main goa…

This study tests whether adding the drug ruxolitinib to the usual two-drug regimen (tacrolimus and methotrexate) can better prevent graft-versus-host disease (GVHD) in children and young adults (ages 2-22) undergoing bone marrow transplant for leukemia or myelodysplastic syndrome…

This study is testing whether a special type of immune cell therapy (CAR-T cells) can be successfully made right at the hospital for children and adults with B-cell acute lymphoblastic leukemia that has come back or not responded to standard treatments. The main goal is to see if…

This study tests a radioactive antibody (211At-BC8-B10) given before a donor stem cell transplant for people with high-risk leukemias or related blood cancers. The antibody targets cancer cells and delivers radiation to help kill them while sparing healthy cells. The goal is to f…

This study tests a new drug called revumenib in people with certain types of leukemia that have returned or not improved with standard treatments. The trial has two parts: first, finding the safest dose, then testing how well it works in four specific groups of patients. About 44…

This study tests a two-step method using lower doses of radiation and chemotherapy before a stem cell transplant for people with various blood cancers or bone marrow failure. The goal is to see if this gentler approach reduces the chance of dying from the transplant itself. About…

This study tests a refined cord blood transplant method for people with hard-to-treat blood cancers like leukemia and lymphoma. Participants receive chemotherapy and radiation before the transplant to kill cancer cells and prepare the body, then donor stem cells are infused to re…

This early study tests whether giving special immune cells (CAR T cells) along with a vaccine can safely help prevent leukemia from coming back after a stem cell transplant. The CAR T cells are made from the donor's immune cells and are designed to attack a protein called CD19 fo…

This study tests the safety and effectiveness of the drug ponatinib in children aged 1 to under 18 with advanced leukemias, lymphomas, or solid tumors that have come back or not responded to other treatments. The goal is to see if ponatinib can shrink or control the cancer. About…

This study tests whether giving patients their own specially matched natural killer (NK) cells after chemotherapy and a cord blood transplant can help keep blood cancers like leukemia and lymphoma from coming back. About 100 adults with various blood cancers will receive NK cells…

This study is for children under 25 who have had a stem cell transplant for blood cancers like leukemia. After transplant, their immune system is weak, putting them at high risk for dangerous infections. Researchers are adding back a specific type of donor cell (CD45RA-depleted) …

This early-phase study is testing whether bone marrow from deceased donors can be safely used for transplants in people with blood cancers like leukemia and lymphoma. About 12 patients will receive either strong or milder chemotherapy before the transplant. Researchers will monit…

This study tests a new treatment for people with certain blood cancers (like lymphoma or leukemia) that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells, which are modified in a lab to better find and attack cancer cells. The go…

This early-phase study tests whether it is safe and possible to collect a patient's own blood stem cells and give them together with CAR-T cell therapy for people with blood cancers that have come back or not responded to treatment. About 20 adults aged 18 to 85 with certain type…

This study tests whether combining two drugs, revumenib and mezigdomide, is safe for people whose acute leukemia has returned or not responded to prior treatment. It includes adults and teens aged 12+ with specific genetic subtypes (KMT2A-r, NUP98-r, or NPM1-m). The first part fi…

This early-stage study tests a new type of immunotherapy for children and young adults up to age 21 whose leukemia has come back or not responded to treatment. The therapy uses the patient's own immune cells, which are modified in a lab to recognize and attack leukemia cells. The…

This early-phase study tests whether adding a radioactive antibody (225Ac-DOTA-daratumumab) to standard chemotherapy and radiation before a donor stem cell transplant is safe and effective for people with high-risk acute myeloid leukemia, acute lymphoblastic leukemia, or myelodys…

This early-stage study tests a new type of stem cell transplant for children whose blood cancer or solid tumor has returned or is hard to treat. Doctors use a special method to remove certain immune cells from the donor's stem cells, then give a drug called zoledronate after tran…

This early-stage study tests a new type of CAR-T cell therapy for people with certain blood cancers (like leukemia and lymphoma) that have come back or not responded to other treatments. The therapy uses a patient's own immune cells, modified to attack cancer cells, and is made w…

This study tests whether a second type of CAR T-cell therapy, targeting CD22, can keep acute lymphoblastic leukemia (ALL) from returning in people who already had CD19 CAR T-cell treatment. About 20 participants aged 3 to 65 who show no signs of cancer after their first CAR T-cel…

This early study tests a new treatment called LV009 injection in 10 adults whose blood cancers (certain types of lymphoma or leukemia) have returned or not responded to standard therapy. The main goal is to check if the treatment is safe. Participants receive the injection and ar…

This study tests a treatment called CAR T-cell therapy for people with advanced B-cell leukemias or lymphomas that haven't responded to standard drugs. Participants' own immune cells are collected, modified in a lab to recognize and attack cancer cells, and then returned to the b…

This study tests a stem cell transplant from a half-matched donor for people with blood cancers. Before the transplant, patients receive chemotherapy and low-dose radiation to prepare the body. The goal is to see if this approach helps the new stem cells grow and fight cancer wit…

This study tests a treatment called obecabtagene autoleucel (obe-cel) for adults with B-cell acute lymphoblastic leukemia (ALL) whose cancer is in complete remission with no detectable cancer cells. The goal is to see if this CAR T cell therapy can help prevent the leukemia from …

This study is for adults with a specific, high-risk type of acute lymphoblastic leukemia called Ph-like ALL. Researchers are testing whether adding targeted drugs (olverembatinib or gecacitinib) and venetoclax to standard chemotherapy can help more patients achieve a deep remissi…

This early-phase trial is testing an experimental oral drug, MRX-2843, in adolescents and adults whose acute leukemia has returned or not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. About 50 participants will take the dr…

This study tests a weight loss program for adult survivors of childhood acute lymphoblastic leukemia (ALL) who are overweight or have obesity. Participants receive a weekly injection of tirzepatide plus remote, supervised resistance exercise three times a week for 28 weeks. The g…

This early-phase study is testing whether adding the targeted drug ruxolitinib to standard chemotherapy is safe for adolescents and young adults (ages 12-39) with a specific high-risk type of acute lymphoblastic leukemia (Ph-like ALL). The trial aims to find the best dose and che…

This study tests a combination of three drugs (venetoclax, cladribine, and low-dose cytarabine) in 36 people aged 15-70 with relapsed or treatment-resistant Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia. The goal is to see how many patients achieve complete…

This study tests a special cell therapy called CAR T for children and young adults with a type of leukemia that has come back or not responded to treatment. Doctors will collect immune cells from the patient, modify them to attack cancer cells, and give them back after chemothera…

This study tests a drug called blinatumomab in infants under 1 year old who have a specific, hard-to-treat type of leukemia (KMT2A-rearranged). The goal is to improve how long these babies stay cancer-free and to help them live longer. About 160 infants will take part, and the tr…

This study is for people with certain blood cancers (like leukemia) who are getting a half-matched bone marrow transplant. Researchers are adding a dose of specially grown immune cells (gamma delta T-cells) after the transplant to see if it can kill any leftover cancer cells whil…

This study tests a two-step immunotherapy approach for people with B-cell acute lymphoblastic leukemia (B-ALL) who are older, too frail for standard chemo, or whose cancer has returned. Participants will receive two targeted drugs in sequence: blinatumomab and inotuzumab ozogamic…

This study tests whether combining two drugs, blinatumomab and asciminib, can help control Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in adults. About 40 participants will receive the combination to see if it is safe and effective. The goal is to mana…

This early-phase trial tests a new treatment for children and adults with acute leukemia that has come back or not responded after a donor stem cell transplant. The treatment uses specially engineered immune cells (T cells) from the original donor that are trained to recognize an…

This study is for children and young adults (ages 1-18) with newly diagnosed B-cell acute lymphoblastic leukemia or lymphoma. It tests a combination of two targeted immunotherapy drugs, inotuzumab and blinatumomab, given early in treatment. The goal is to see if this approach can…

This study offers a CAR T-cell therapy called brexucabtagene autoleucel to people with mantle cell lymphoma or acute lymphoblastic leukemia whose commercially made treatment batch didn't pass quality checks. Participants must have a batch that still meets the study's safety stand…

This early-phase trial tests whether a new type of CAR T cell therapy (UCD19) is safe and can work in adults with B-cell acute lymphoblastic leukemia (B-ALL) who are in first remission but still have tiny amounts of cancer cells (minimal residual disease). About 29 participants w…

This study tests whether adding a new targeted drug to standard chemotherapy helps adults with newly diagnosed acute T-lymphocytic leukemia live longer. About 154 participants will be randomly assigned to get either the new combo or chemo alone. The main goal is to see if the com…

This early-phase study tests the safety and best dose of revumenib, a drug that blocks a protein fueling leukemia growth, in 27 adults and children with specific genetic types of acute leukemia. Participants take revumenib after a stem cell transplant to help keep the cancer from…

This early-phase study tests a new stem cell treatment called Orca-T, combined with targeted radiation and chemotherapy, for people aged 60-75 with acute leukemias or myelodysplastic syndrome (MDS). The goal is to find the safest dose and see how well the body tolerates the treat…

This study tests a second type of CAR T-cell therapy (CD22 CAR T) for children and young adults whose B-cell leukemia came back after standard CD19 CAR T treatment. About 20 participants will receive the new cells 28 to 42 days after the first therapy. The main goals are to check…

This study tests whether giving a CMV vaccine to stem cell donors can protect transplant recipients from CMV infection. Donors receive the vaccine before donating stem cells, and the immunity is passed to the patient. The trial involves 216 people with blood cancers and aims to r…

This early-phase trial tests a vaccine (CMV-MVA Triplex) given to both stem cell donors and recipients to boost immunity against cytomegalovirus (CMV) and prevent active infection after transplant. About 46 people with various blood cancers or disorders will take part. The goal i…

This study tests whether giving a specific type of chemotherapy (intrathecal) before and during treatment with the drug blinatumomab can prevent nerve-related side effects in adults with a type of leukemia called B-cell acute lymphoblastic leukemia. The trial involves 20 particip…

This study tests a 6-month virtual dietary education program (PEDALL) to prevent overweight and obesity in children and teens (ages 5-21) with acute lymphoblastic leukemia (ALL) during maintenance chemotherapy. The program is offered in English and Spanish and includes 376 partic…

This study tests whether a home-based program of computer brain games and mindfulness exercises can improve thinking, memory, and emotional well-being in children and teens who have been treated for leukemia. About 40 participants, ages 8 to 18, will be randomly assigned to start…

This small study tests whether a supervised exercise program can help children and teens (ages 5-17) with acute lymphoblastic leukemia maintain or regain muscle strength during early treatment. Researchers will monitor kids who show signs of weakness after 5 weeks of chemotherapy…

This study tests a program called MedSupport that helps families of children with acute lymphoblastic leukemia give their daily chemotherapy at home. Missing even a few doses can raise the risk of cancer coming back. The program works with hospitals, doctors, and parents to find …

This study looks at whether coloring mandalas before intrathecal chemotherapy (a spinal tap with chemo) can reduce fear and anxiety in children with leukemia. About 60 children aged 4 to 12 will participate. Researchers will measure their fear and anxiety using special scales bef…

This study looks at how radiation and chemotherapy change the bone marrow in people with acute leukemia. Researchers will use special scans and collect blood and bone marrow samples to track these changes over time. The goal is to learn more, not to test a new treatment. About 74…

This study looks at how the heart and lungs work during exercise in young people (ages 8-25) who have survived a heart transplant, leukemia, or were born with chronic lung disease. Researchers will use special tests to measure oxygen use and heart function while participants exer…

This study enrolls children aged 1 to 18 with newly diagnosed acute lymphoblastic leukemia, lymphoblastic lymphoma, or mixed phenotype acute leukemia. The main goal is to give enough initial treatment while doctors gather genetic and lab information to decide the best risk-based …

This study examines stored umbilical cord blood from 300 children who later developed leukemia. Researchers will check the cord blood for the same genetic changes found in the children's leukemia cells. The goal is to understand how and when these changes first appear before birt…

This study collects blood and tissue samples from 2000 people—some with cancer, some without—to create a blinded reference set. Researchers will use these samples to evaluate how well new blood tests can detect many types of cancer early. The goal is to improve the accuracy of mu…

This study follows 100 children with acute lymphoblastic leukemia (ALL) to see how the steroid dexamethasone moves through their blood and spinal fluid, and whether it affects bone density or causes nerve side effects. Participants continue their standard treatment and provide ex…

This study screens children and young adults (under 22) with leukemia that has returned or is difficult to treat. By analyzing their blood and bone marrow, doctors can identify specific genetic markers to match them with the most promising experimental treatments. The goal is to …

This study aims to find genetic markers in saliva that could predict liver damage caused by asparaginase, a common chemotherapy drug for acute lymphoblastic leukemia. Researchers will collect saliva samples from 500 newly diagnosed patients and track who develops liver problems. …

This study looks at whether CAR-T cell therapy, a new immune treatment for blood cancers, can cause early heart problems. Researchers will use ultrasound to check heart function in 60 patients before and a few days after treatment. The goal is to find out how often these heart is…

This study is a large registry that gathers medical information and biological samples from 10,000 adults with acute lymphoblastic leukemia (ALL) and similar blood cancers. The goal is to track how patients are diagnosed, treated, and how they fare over time, in order to improve …

This study will look at the medical records of 18,000 children, adolescents, and young adults with cancer in low- and middle-income countries. The goal is to understand how often treatment fails or causes harmful side effects, especially for leukemia and lymphoma. The findings wi…

This study looks at whether frequent blood and bone marrow tests can help doctors know if a child's leukemia will come back after CAR T-cell therapy. About 60 children and young adults aged 1 to 25 who have no signs of cancer after CAR T-cells will be followed for 2 years. The go…

This study looks at whether finding leukemia stem cells in the blood and bone marrow can better predict when childhood acute myeloid leukemia will come back. About 283 children newly diagnosed with AML will be followed to see if these cells are more accurate than current tests. T…

This study uses data from about 475 people with acute lymphoblastic leukemia (ALL) who have received the drug Erwinase. The goal is to create a computer model that helps doctors give the right dose to balance effectiveness and reduce side effects like high ammonia levels. The res…

This study is testing a new mobile app that sends timely reminders and support to help teens and young adults (ages 14-29) with acute lymphoblastic leukemia or lymphoma take their oral chemotherapy pills as prescribed. The study enrolls 60 participants who are in the maintenance …

This study looks at how the body absorbs, breaks down, and gets rid of a radioactive form of the drug bleximenib in 10 people with acute leukemia. Participants have a type of leukemia that has come back or not responded to other treatments. The goal is to understand the drug's pa…

This study looks at how young adult survivors of childhood leukemia feel about exercise. Researchers will use a special test and interviews to understand their emotions and thoughts about being active. The goal is to learn how to help them become more physically active in the fut…